bioMerieux (OTCMKTS:BMXMF) Stock Now Rated “Hold” by Wall Street Analysts

bioMerieux (OTCMKTS:BMXMF) has received an average rating of “Hold” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company.

A number of analysts have commented on the stock. Zacks Research raised shares of bioMerieux from a “strong sell” rating to a “hold” rating in a research report on Monday, September 28th. Deutsche Bank Aktiengesellschaft raised bioMerieux from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, Morgan Stanley reaffirmed an “underweight” rating on shares of bioMerieux in a research note on Friday, September 11th.

bioMerieux Price Performance

BMXMF opened at $102.14 on Monday. bioMerieux has a twelve month low of $77.00 and a twelve month high of $132.05. The company has a 50-day simple moving average of $89.69 and a 200 day simple moving average of $94.51.

bioMerieux Company Profile

bioMérieux is a France-based company specializing in in vitro diagnostics. It develops and manufactures diagnostic systems, reagents, software and services used to detect disease, identify infectious organisms and support treatment decisions. Its offerings serve hospitals, clinical laboratories and other healthcare providers, with a particular focus on infectious diseases, antimicrobial resistance and syndromic testing.

The company also provides industrial microbiology solutions for applications such as food safety, pharmaceutical manufacturing and quality control.